| Description | Cemiplimab (Anti-Human PD-1) is a human monoclonal antibody against programmed cell death receptor 1 (PD-1) and a checkpoint inhibitor that blocks PD-1/PD-L1 mediated T-cell inhibition and can be used in metastatic cancer and squamous cell skin cancer research. |
| In vivo | 在一项使用MC38.Ova肿瘤的小鼠模型中，Cemiplimab（10 mg/kg ，两周内五次腹腔注射）在与REGN3767[2]联合的免疫疗法中，增加了肿瘤及其淋巴结(dLNs)中效应T细胞的比例，从而抑制了肿瘤生长。 |
| Synonyms | REGN-2810, SAR-439684 |
| molecular weight | N/A |
| CAS | 1801342-60-8 |
| Storage | store at low temperature | store at -20°C |
| References | 1. Michael R Migden, et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018 Jul 26;379(4):341-351. 2. Elena Burova, et al. Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice. Mol Cancer Ther. 2019 Nov;18(11):2051-2062. |